Endocrine Abstracts

Silent corticotroph tumors (SCT) represent a distinct subtype of pituitary tumors (PT) known for their potential aggressiveness, surpassing other silent PTs like gonadotroph tumors (SGT). Despite their aggressive clinical behavior, the mechanisms underlying their aggressiveness remain unclear. Recent studies in various cancers, such as breast cancer, have implicated the IGF1 axis in the presence of metastases. This study aims to investigate some components of the somatotroph a...

Introduction: Hypophysitis, an infrequent inflammatory condition of the pituitary gland, is typically managed with glucocorticoids, reserving surgery for significant mass effects and considering immunosuppressants or radiotherapy for refractory cases. Recent reports indicate positive outcomes with immunosuppressants. Here, we present a case of recurrent xanthogranulomatous hypophysitis in a 16-year-old female successfully treated with Rituximab.Case Repo...

Corticotroph tumours, comprising around 15% of pituitary tumours, express ACTH and other peptides originating from TPIT-lineage adenohypophyseal cells. Their tumorigenesis involves a complex interplay of genetic and epigenetic factors and hormonal and growth factor stimulation. Silent corticotroph tumours (SCT) share immunopositivity for ACTH and TPIT with functioning corticotroph tumours (FCT) but do not exhibit evidence of hypercortisolism. Despite their aggressive growth an...

Background: There is an increasing interest to find specific prognostic markers of the aggressive behaviour of some pituitary adenomas (PA). The most studied markers have been the immunohistochemical staining for Ki-67 and p53. The aim of this study was to evaluate the relevance as possible prognostic markers of growth factors (IGF1R), angiogenic factors (VEGF and his receptor) and new genes (PTTG) versus the immunohistochemical expression of Ki-67 and p53 in PA.<p class="...